1/7/25 - $nvo - Probs a buy in low 80s... but...
1/7/25 :: VROCKSTAR :: 
NVO
Probs a buy in low 80s... but...
Friend who highlighted some good calls last year DM'd me (ty!) about this one. Figured i'd copy/paste my response in case anyone could add to this logic or is more knowledgeable on catalysts timing etc.
1/ i typically stay away from pharma (mainly bc i look at so many sectors and this is the singular one i've never covered professionally)
2/ the financials look great. growth, margins, cf generation - all "A" grade
3/ unclear how the
SAVA result will affect px performance in the coming days given diabetes seems to be a relevant part of the portfolio (but obviously this is a mega diversified name)
so in short, it's defn a buy here, but given my conviction on maybe 5 other names that i can really size up, i've set an even greedier entry look closer to sub $80... not that i'd not own it here, but just i don't want to overcomplicate my book at the moment while i'm moving/ shaking aggressively on other stuff.
4/ also, what the banana hammock happened on dec 19 - unlocking that "event's bottom"/ implication looks like the key to determining how low this goes. it's already massively oversold, so if it wicks much further, it's simply a buy on mean reversion anyway - could probably pick up an easy 5+% under $80 without even trying (which is my lazy approach here). but i don't fault u if u own it - looks legit.
5/ options chain implying meager MT move keeps me wondering if this is dead money for the immediate term and i should only be a greedy buyer in the mid 70s. i think there's a way to generate yield here, but feels too risk adverse for my style (high octane) until i can gear it up at these lower levels with a better sense for mkt rippity-do-dah
so - what do u think, anon?
V
NVOProbs a buy in low 80s... but...
Friend who highlighted some good calls last year DM'd me (ty!) about this one. Figured i'd copy/paste my response in case anyone could add to this logic or is more knowledgeable on catalysts timing etc.
1/ i typically stay away from pharma (mainly bc i look at so many sectors and this is the singular one i've never covered professionally)
2/ the financials look great. growth, margins, cf generation - all "A" grade
3/ unclear how the
SAVA result will affect px performance in the coming days given diabetes seems to be a relevant part of the portfolio (but obviously this is a mega diversified name)so in short, it's defn a buy here, but given my conviction on maybe 5 other names that i can really size up, i've set an even greedier entry look closer to sub $80... not that i'd not own it here, but just i don't want to overcomplicate my book at the moment while i'm moving/ shaking aggressively on other stuff.
4/ also, what the banana hammock happened on dec 19 - unlocking that "event's bottom"/ implication looks like the key to determining how low this goes. it's already massively oversold, so if it wicks much further, it's simply a buy on mean reversion anyway - could probably pick up an easy 5+% under $80 without even trying (which is my lazy approach here). but i don't fault u if u own it - looks legit.
5/ options chain implying meager MT move keeps me wondering if this is dead money for the immediate term and i should only be a greedy buyer in the mid 70s. i think there's a way to generate yield here, but feels too risk adverse for my style (high octane) until i can gear it up at these lower levels with a better sense for mkt rippity-do-dah
so - what do u think, anon?
V
Trade active
bought some jan 31 2025 $75 C's for $6 bucks. small trading position on reversion. but low conviction (5 or 6 out of 10 idea)
V
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.